Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Genetic variation in rotavirus serotype 4 subtypes.

K Y Green¹, A Sarasini, Y Qian

¹National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892.

|May 1, 1992

Summary

Rotavirus serotype 4 strains show two subtypes (A and B) based on VP7 glycoprotein variations. Amino acid changes in VP7, particularly at antigenic sites, may explain these rotavirus subtype differences.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Six-month humoral and cellular immune response to the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors: a longitudinal cohort study with a focus on the variants of concern.

ESMO open·2022

Same author

Human cytomegalovirus (HCMV) long-term shedding and HCMV-specific immune response in pregnant women with primary HCMV infection.

Medical microbiology and immunology·2022

Same author

Humoral and cellular response before and after the fourth BNT162b2 vaccine dose in patients with solid tumors on active treatment.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Same author

Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.

ESMO open·2022

Same author

Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.

ESMO open·2022

Same author

A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study.

ESMO open·2021

Area of Science:

Virology
Immunology
Molecular Biology

Background:

Rotavirus is a leading cause of severe diarrheal disease in infants and young children worldwide.
Serotype 4 rotavirus strains are classified into two antigenic subtypes, A and B, using immune electron microscopy.
The outer capsid glycoprotein VP7 is a major determinant of rotavirus serotype specificity.

Purpose of the Study:

To investigate the molecular basis of antigenic differences between serotype 4 rotavirus subtypes.
To compare the amino acid sequences of the VP7 gene from subtype A and subtype B strains.
To identify specific amino acid residues responsible for subtype divergence.

Main Methods:

Solid phase immune electron microscopy for antigenic classification.

Related Experiment Videos

Gene sequencing of the VP7 outer capsid glycoprotein.

Deduced amino acid sequence comparison between different strains.

Main Results:

Fifteen divergent amino acid residues were identified between subtype A and subtype B VP7.
These divergent residues were conserved within each subtype.
Three critical amino acid substitutions (at positions 96, 212, and 217) were located in serotype-specific antigenic sites of VP7.

Conclusions:

VP7 subtype differences in serotype 4 rotavirus are likely due to specific amino acid substitutions within immunodominant antigenic sites.
These substitutions may contribute to the antigenic variation observed in rotavirus strains.
Further research is needed to determine the epidemiological significance of these VP7 subtype variations.